Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT

Inclusion Criteria: * Squamous cell carcinoma of the larynx or hypopharynx, histologically proven, locally advanced: * T2 not accessible to a supra-cricoid partial laryngectomy or not, * T3 without massive infiltration by endolarynx transglottic injury, * N0 to N2c * No distant metastasis * No associated cancer or earlier * Patients Previously Untreated * Age\> 18 years and \<75 years * PS 0 or 1 according to WHO * Tumor volume assessable by RECIST. * Absence of distant metastasis, confirmed by chest TDM, abdominal ultrasound (or TDM) in case of abnormal liver function and bone scan if local symptoms. * Absence of any participation in a clinical trial within 30 days prior to inclusion. * Absence of any concomitant cancer treatment. * Absence of any chronic treatment ( ≥3 months) with a daily corticosteroid dose is ≥20 mg / day of methylprednisolone or equivalent. * Hematological function: neutrophils ≥1.5 x 109 / L, platelets ≥100 x 109 / l, hemoglobin ≥10 g / dl (or 6.2 mmol / l). * Hepatic function: normal total bilirubin; AST (SGOT) and ALT (SGPT) ≤ 2.5 x ULN (LNS) of each center; alkaline phosphatase ≤ 5 x LNS. * Renal function: serum creatinine ≤ 120 mol / l (1.4 mg / dl); if creatinine \> 120 mol / l, creatinine clearance should be ≥ 60 ml / min. * calculated creatinine clearance (Crockcroft formula) or measured ≥ 60 ml / min * Estimated life expectancy ≥ 3 months * Weight loss less than 10% over the last 3 months * Patient has given its written consent befo…